Share on StockTwits

PDL BioPharma (NASDAQ:PDLI) is scheduled to announce its Q114 earnings results on Monday, May 12th. Analysts expect the company to announce earnings of $0.45 per share and revenue of $130.93 million for the quarter.

PDL BioPharma (NASDAQ:PDLI) last posted its quarterly earnings results on Monday, March 3rd. The company reported $0.39 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.43 by $0.04. The company had revenue of $110.10 million for the quarter, compared to the consensus estimate of $115.22 million. During the same quarter in the prior year, the company posted $0.34 earnings per share. The company’s quarterly revenue was up 28.0% on a year-over-year basis. On average, analysts expect PDL BioPharma to post $1.84 EPS for the current fiscal year and $2.00 EPS for the next fiscal year.

Shares of PDL BioPharma (NASDAQ:PDLI) opened at 8.33 on Friday. PDL BioPharma has a 52 week low of $7.38 and a 52 week high of $10.21. The stock’s 50-day moving average is $8.31 and its 200-day moving average is $8.52. The company has a market cap of $1.336 billion and a price-to-earnings ratio of 5.07.

A number of analysts have recently weighed in on PDLI shares. Analysts at Zacks reiterated a “neutral” rating on shares of PDL BioPharma in a research note on Tuesday, April 22nd. They now have a $8.75 price target on the stock.

PDL BioPharma, Inc (NASDAQ:PDLI) is a is a biotech company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.